Merkel C, Gatta A, Donada C, Enzo E, Marin R, Amodio P, Torboli P, Angeli P, Cavallarin G, Sebastianelli G
Department of Clinical Medicine, University of Padua, Italy.
Hepatology. 1995 Sep;22(3):808-13. doi: 10.1002/hep.1840220318.
The association beta-blockers plus nitrates has been reported to impair renal function and renal sodium handling, leading to increased risk of development of ascites, or worsening of a preexisting ascites, or increase in the requirements of diuretic agents. In 81 patients with cirrhosis and esophageal varices, participating in a multicenter controlled clinical trial of prophylaxis of variceal bleeding comparing nadolol (NAD) plus isosorbide-5-mononitrate (I5M) with NAD alone, renal function, presence of ascites, and diuretic requirements were assessed at inclusion and after 6 months of follow-up. No significant variation in s-urea or s-creatinine was observed in either group, Three patients in the nadolol group and two in the NAD plus I5M developed ascites at 6 months (P = .70), and a need to increase diuretic regimen was observed in four and three patients, respectively (P = .76). Decrease in heart rate and in mean arterial pressure was similar in the two groups. There was a significant correlation between increases in s-creatinine and decrease in mean arterial pressure in the whole series (P = .015). Only in patients treated with the association was there a significant larger proportion of patients ascitic who became anascitic, than of patients anascitic who became ascitic (P = .03). In patients treated with the association, there was a significantly larger decrease in hepatic venous pressure gradient (P = .05). It is concluded that patients treated with the association NAD plus I5M are not at increased risk of developing renal dysfunction or worsening of ascites compared with patients treated with NAD alone.(ABSTRACT TRUNCATED AT 250 WORDS)
据报道,β受体阻滞剂与硝酸盐联用会损害肾功能和肾脏对钠的处理,导致腹水形成风险增加、原有腹水恶化或利尿剂需求增加。在一项多中心对照临床试验中,81例肝硬化和食管静脉曲张患者参与了比较纳多洛尔(NAD)加5-单硝酸异山梨酯(I5M)与单用NAD预防静脉曲张出血的研究,在入组时和随访6个月后评估了肾功能、腹水情况及利尿剂需求。两组患者的血清尿素或血清肌酐均无显著变化。纳多洛尔组有3例患者、NAD加I5M组有2例患者在6个月时出现腹水(P = 0.70),分别有4例和3例患者需要增加利尿剂治疗方案(P = 0.76)。两组心率和平均动脉压的下降相似。在整个研究系列中,血清肌酐升高与平均动脉压下降之间存在显著相关性(P = 0.015)。仅在联合用药治疗的患者中,腹水消退的患者比例显著高于腹水出现的患者比例(P = 0.03)。在联合用药治疗的患者中,肝静脉压力梯度显著下降(P = 0.05)。得出的结论是,与单用NAD治疗的患者相比,接受NAD加I5M联合治疗的患者发生肾功能障碍或腹水恶化的风险并未增加。(摘要截短至250字)